Paris

• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical … Recruiting
  2024-514886-21-00 6 2024-11-06 Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (P
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 5 2024-11-05 lupus nephritis
• Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting
  2024-514354-67-00 5 2024-11-01 Systemic lupus erythematosus
• Efficacy and Safety of Obinutuzumab versus Rituximab in childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : à double-bli … Recruiting
  2024-514240-93-00 10 2024-10-31 Idiopathic nephrotic syndrome (INS)
• A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i … Recruiting
  2024-514899-41-00 4 2024-10-31 Breast cancer
• Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting
  2023-505334-10-01 7 2024-10-30 Unresectable, Locally Advanced, or Metastatic Solid Tumors
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• LENVABLA Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by percutaneous ablatio … Recruiting
  2024-514606-31-00 4 2024-10-29 Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
• QUIDOSE. Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary s … Recruiting
  2024-516101-23-00 5 2024-10-28 Sarcoidosis
• BevacizuMAV : Evaluation of the efficacy and safety of anti-angiogenic treatment with intravenous bevacizumab in patients with symptomatic c … Recruiting
  2023-508464-30-00 4 2024-10-24 cerebral arteriovenous malformations
• Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide Recruiting
  2024-511026-31-01 4 2024-10-24 Glioblastoma grade 4
• Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF … Recruiting
  2024-511858-44-00 7 2024-10-24 Inclusion Body Myositis
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• study of pembrolizumab in classic or endemic Kaposi’s sarcoma Recruiting
  2024-514241-10-00 4 2024-10-22 Kaposi's sarcoma
• Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis Recruiting
  2023-504755-26-00 4 2024-10-21 Bronchiectasis
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporeal photopheresis as first-li … Recruiting
  2023-508614-41-00 4 2024-10-15 The study will be proposed to all adult patients receiving an allogene
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• 68Ga-FAPI-46 PET/CT for predicting histological response in triple-negative breast cancer Recruiting
  2023-507860-37-00 9 2024-10-14 Breast cancer
• TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study Recruiting
  2024-514906-30-00 5 2024-10-14 "double diabetes"

Showing 865–888 of 2,286 trials